Glucose Disposal & Insulin Sensitivity
In a randomized, placebo-controlled study of type 2 diabetic patients on metformin, ATX-304 markedly reduced fasting plasma glucose and HOMA-IR, confirming its capacity to suppress hepatic gluconeogenesis and enhance skeletal-muscle glucose uptake via AMPK activation [1].
Lipid & Cardiovascular Support
Preclinical data demonstrate that ATX-304 reduces hepatocellular lipid droplets, alleviates steatosis, and improves vascular markers—effects visualized by histological clearance of liver lipid accumulation and enhanced endothelial function in murine models [2].
Mitochondrial Energy Metabolism
In aged mice, chronic ATX-304 treatment stimulated AMPK-mediated mitochondrial biogenesis, leading to increased cardiac output, improved microvascular perfusion, and greater exercise capacity—mirroring key benefits of endurance training without exercise [3][4].
References
- AMPK activated protein kinase in T2D: https://pubmed.ncbi.nlm.nih.gov/29925691/
- ATX-304 clears liver lipid droplets & improves endothelial function: https://insight.jci.org/articles/view/179990/figure/2
- ATX-304 exercise-mimetic effects in aged mice: https://pubmed.ncbi.nlm.nih.gov/29925691/
- Age-related metabolic improvements in mice: https://www.nature.com/articles/s42003-021-02837-0
Note: BioAmp is supplied strictly for investigational research use only. It is not approved or intended for diagnostic or therapeutic applications in humans or animals.
Reviews
Clear filtersThere are no reviews yet.